Reset filter
Palavras-chave
Tumores de la Próstata ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

264 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

On-Study - Prostate Cancer - Localized Disease On-Study Form - 2262683v3.0 - Prostate Cancer - Localized Disease On-Study Form

- 09/01/2015 - 1 Formulário, 2 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Prostate: Disease Description - Localized
Prostate Cancer - Localized Disease On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DC4FD317-E0EB-5D4E-E034-0003BA12F5E7

E1805 On-Study Form

- 16/06/2015 - 1 Formulário, 8 Grupos de itens, 45 Elementos de dados, 1 Idioma
Grupos de itens: Header, Patient demographics, Data amendment, Description of Primary Disease, Radiographic Evidence, Baseline PSA Value, Prior therapy, Comments
E1805 On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0F2A22D3-D6F2-3C2D-E044-0003BA3F9857

On-Study - Prostate Cancer - Non-Localized Disease On-Study Form - 2263681v3.0 - Prostate Cancer - Non-Localized Disease On-Study Form

- 17/09/2021 - 1 Formulário, 5 Grupos de itens, 50 Elementos de dados, 1 Idioma
Grupos de itens: CRF Header, Prostate: Initial Diagnosis, Prostate: Prior Treatment, Prostate: Disease Status, Prostate: Metastatic/Recurrent Site(s)
Prostate Cancer - Non-Localized Disease On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DC4FE213-706E-5DF9-E034-0003BA12F5E7

Prostate Cancer NCT00430183 On-Study - CALGB 90203: On-Study Form - 2524962v1.0 - CALGB 90203: On-Study Form

- 09/01/2015 - 1 Formulário, 10 Grupos de itens, 65 Elementos de dados, 1 Idioma
Grupos de itens: Header Module, Performance Status, INITIAL DIAGNOSIS, Laboratory Values at Study Entry, PRE-ENROLLMENT PSA ASSESSMENTS, PRE-ENROLLMENT PSA ASSESSMENTS, PRE-ENROLLMENT PSA ASSESSMENTS, Prior Hormonal Therapy, Other Prior Therapy, Footer Module
CALGB 90203: On-Study Form [Form C-1239] Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1EEA73A2-08B9-6F29-E044-0003BA3F9857

CALGB: 90202 On-Study NCT00079001

- 20/09/2021 - 1 Formulário, 10 Grupos de itens, 67 Elementos de dados, 1 Idioma
Grupos de itens: Header, Patient demographics, INITIAL DIAGNOSIS, PRIOR TREATMENT, CURRENT SUPPLEMENTS, Current Treatment, METASTATIC/RECURRENT SITE(S), Performance Status, LABORATORY VALUES, Footer MODULE
CALGB: 90202 On-Study NCT00079001 Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B4607705-4BBB-0537-E034-0003BA12F5E7

dbGaP phs000838 Ghana Prostate Study - Eligibility

- 09/03/2024 - 5 Formulários, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: Michael B Cook, PhD, National Cancer Institute, NIH, Rockville, MD, USA MeSH: Prostatic Neoplasms,Prostatic Hyperplasia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000838 Participants were recruited through the Ghana Prostate Study-a population-based component, and a clinical component. The population-based component was a probability sample designed using the 2000 Ghana Population and Housing Census data in an attempt to recruit approximately 1,000 men aged 50-74 years in the Greater Accra region (~3 million people), which successfully recruited 1,037 healthy men between 2004 and 2006 with a response percentage of 98.8 %. Consented individuals underwent an in-person interview, and within 7 days had a digital rectal examination (DRE) and provided an overnight fasting blood sample for prostate-specific antigen (PSA) testing, biomarker assays, and genetic analysis. Subjects who had a positive screen by PSA (2.5 ng/ml) or DRE underwent a transrectal ultrasound-guided biopsy. A total of 73 histologically confirmed prostate cancer cases were identified through the population-based screening component of the Ghana Prostate Study and were included in the case population in the published GWAS (Cook et al., Human genetics, 2013). From the remaining 964 screen-negative individuals, 836 had at least 20 μg DNA extracted and available for analysis, and 500 of these were matched to cases for analysis by age (in 5-year categories). In the Ghana Prostate Study, we recruited 676 prostate cancer cases at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012. All consented cases were interviewed and provided an overnight fasting blood sample. At the time of selection for this analysis we had recruited 582 prostate cancer cases, from which we selected 427 for analysis. Combined with the 73 cases diagnosed through the population-based component of the study, this yielded 500 available prostate cancer cases for analysis.

pht004796.v1.p1

1 Grupo de itens 3 Elementos de dados

pht004797.v1.p1

1 Grupo de itens 3 Elementos de dados

pht004798.v1.p1

1 Grupo de itens 7 Elementos de dados

pht004799.v1.p1

1 Grupo de itens 5 Elementos de dados

ECOG E3805 On-Study Form NCT00309985

- 16/06/2015 - 1 Formulário, 11 Grupos de itens, 78 Elementos de dados, 1 Idioma
Grupos de itens: ECOG clinical trial administrative data, Data amendment, Patient status, Description of Primary Disease, Extent of Disease, Prior Treatment (for this disease), Baseline PSA Value, Androgen Deprivation , Metabolic Syndrome, Baseline Abnormalities, Comments
ECOG E3805 On-Study Form NCT00309985 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F96DE7A1-1997-4F8E-E034-0003BA3F9857

CALGB: 90401 ON-STUDY FORM NCT00110214

- 16/06/2015 - 1 Formulário, 9 Grupos de itens, 82 Elementos de dados, 1 Idioma
Grupos de itens: Header, Patient demographics, INITIAL DIAGNOSIS, DISEASE ASSESSMENT, REQUIRED LAB DATA AT STUDY ENTRY, PSA ASSESSMENTS, medication history, Opiate medication history, COMMENTS
CALGB: 90401 ON-STUDY FORM NCT00110214 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EF4A7704-E232-4EC4-E034-0003BA3F9857

Concomitant Medications GSK study Prostatic neoplasms NCT00883909

- 26/11/2017 - 1 Formulário, 3 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Concomitant Medications, Concomitant Medication
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

TNM Staging GSK study Prostatic neoplasms NCT00883909

- 26/11/2017 - 1 Formulário, 2 Grupos de itens, 6 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, TNM Staging History
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

PSA results GSK study Prostatic neoplasms NCT00883909

- 26/11/2017 - 1 Formulário, 2 Grupos de itens, 4 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, PSA results
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Screen visit GSK study Prostatic neoplasms NCT00883909

- 26/11/2017 - 1 Formulário, 6 Grupos de itens, 17 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Subject number Previous, Inclusion Exclusion Criteria, Inclusion/Exclusion Criteria, Eligibility Criteria, Investigator Statement
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial